Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins
Lymphomas are comprised of a diversity of tumors with different pathologic and clinical
features. While distinct differences in gene expression profiles have been elucidated in
different lymphomas, there has been inconsistent correlation with the few published
Greater insights into the biology of lymphomas may be achieved by integrating current
genomic information with additional studies focused on the interrelationships in tumors of
the patterns of chromatin protein expression, chromatin protein modification, and RNA
expression profiling (both within bulk tumor and within specific microscopic tumor niches
accessible by microdissection and cell sorting approaches).
The goals of this protocol are to identify the global levels of all histones (including
variant histones) and non-histone chromosomal proteins, and to measure the relative levels
of most known covalent modifications on histone and non-histone chromosomal proteins.
For a limited number of cases illustrative of selected pathological entities, we propose to
map the genome-wide distribution of those modifications judged to be biochemically
This work will involve the analysis of a broad panel of lymphoma and lymphoid samples, which
were previously procured under multiple protocols at the NIH, and for which there is excess
tissue available for research. We also request permission to extend this analysis to surplus
materials to be accrued under existing protocols, upon completion of all superseding
diagnostic tests and medical/scientific studies. The criteria for inclusion in this study
are subsumed under the enveloping protocols. The number of cases to be included is dependent
upon the size of these protocols; because statistical significance improves with increasing
numbers. We hope to include up to 300 cases.
Lysates from surplus samples will be prepared and arrayed onto microarrays.
These arrays will be probed with panels of protein and modification specific antibodies.
The antibody reactivity will be quantified and samples will be subjected to statistical
analysis, especially hierarchical clustering to correlate patterns of reactivity with
clinical and histological features.
Representative cases for which sufficient surplus tissue remains will be subjected to
ChIP-Seq to map the distribution of modifications across the genome.
Time Perspective: Retrospective
David L Levens, M.D.
National Cancer Institute (NCI)
United States: Federal Government
|National Cancer Institute (NCI), 9000 Rockville Pike||Bethesda, Maryland 20892|